The number of tested samples has increased significantly from a daily average of 230k during the first week of July '20 to almost two million daily samples tested in May with the ongoing second wave of the pandemic which began in India in March '21. The COVID-19 vaccination programme in India commenced on Jan 16th '21 with approx. 155 million vaccine doses administered up to May 1 (for more information on vaccination status, refer to the embedded report above). Two vaccines have so far been approved, ie Covashield (developed by Oxford-AstraZeneca) manufactured by Serum Institure of India and Covaxin (developed by Bharat Biotech in collaboration with ICMR) manufactured by Bharat Biotech. Other COVID-19 vaccines that are in the regulator approval pipeline and/or at an advanced vaccine trial stage include Sputnik V (Gam-COVID-Vac) developed by Russia's Gamaleya National Centre of Epidemiology and Microbiology and the ZyCoV-D plasmid DNA vaccine developed by Zydus Cadila.